Biocon Limited has informed the Exchange about press release dated 14-Nov-2022 titled "Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% ; Gross R&D Spend at Rs 252 Crore, Up 52%; Biosimilars Up 34%; Research Services Up 26%; Generics Up 18%."